

Index

- A β amyloid 214
- A β deposition in AD 177
- acceruloplasminaemia 150–3
 - animal models 205
 - clinical findings 152
 - disease mechanism 151
 - first case reported 151
 - increase in brain iron 152–3
 - therapeutic strategies 183
- acetyl choline
 - in AD 93
 - in PD 72
- acquired immunodeficiency syndrome 164
- acrolein 28
- action potential 1–2
- acyl-coenzyme A 179
- alcohol dehydrogenase (ADH) 69
- alcohol in PD 69
- aldehydes 27–8
- 2-alkenals 27
- aluminium in AD 87
- Alzheimer's disease (AD) ix, 38, 77–94
 - A β deposition 177
 - A β life preservers 82
 - abnormal metal homeostasis 197
 - abnormalities of neurotransmitter pathways 176
 - acetyl choline in 93
 - aggregated and soluble fractions of A β 80
 - amyloidosis in 77
 - animal models 196–9
 - clinical symptoms 77
 - copper in 83–8
 - cytokine-mediated inflammatory processes 92
 - dietary intake 175
 - drug strategies 174–5
 - early-onset 88, 177
 - genetic factors 88–9
 - hist-pathological findings 78
 - histology 77
 - hypothetical mechanisms of conformational transitions for A β peptides 80
 - iron in 83–8
 - membrane-bound A β 85
 - metal involvement 83–8
 - metallobiology of A β 84
 - mitochondrial function 89
 - nicotinic receptors in 177
 - oxidative stress in 89–93
 - prevalence 77
 - proteins involved in 78–83
 - risk factors 88–9, 174
 - symptoms 77
 - therapeutic strategies 174–9
 - transgenic models 196
 - treatment strategies 185
 - vaccine 176
 - zinc in 83–8
- amino acid sequences
 - alignment and relationships of synuclein sequences 54–5
 - eukaryotic frataxins 116
- α -amino-3-hydroxy-5-methyl-4-isoxalolepropionate (AMPA)/kainate receptors 4, 47

- β -amyloid ix, 83
 amyloid fibres 51
 β -sheets in 128
 amyloid fibrils 212
 amyloid precursor protein (APP) 78, 85–9, 198
 α - and β -secretase processing 82
 degradation 83
 intracellular domain (AICD) 78
 proteolytic processing 79
 amyloid structure models 129
 amyloidogenesis 80
 amyloidosis 49–50
 in AD 77
 amyotrophic lateral sclerosis (ALS) 137–49
 and superoxide dismutase (SOD) 139–42
 animal models 203–5
 cytoprotection against 30–5
 disease mechanisms 142–5
 excitotoxicity and decreased glutamate uptake
 by astroglia 145
 genetic risk factors 138
 genetics 138
 intracellular protein aggregates in
 143–4
 major genes involved 137–9
 microglia in 147
 mitochondrial damage 145
 neurofilament disorganization 143
 oxidative damage in 142–3
 prevalence 137
 principal causes 142
 therapeutic strategies 181–3
 androgen receptor 101
 ligand binding domain 106
 mechanism of action 105–9
 androgen response elements (ARE) 106
 animal models 189–210
 aceruloplasminaemia 205
 Alzheimer's disease 196–9
 amyotrophic lateral sclerosis (ALS)
 203–5
 experimental autoimmune encephalitis
 (EAE) 206–7
 fragile X mental retardation disease 201
 Friedreich's ataxia 200–1
 Huntington's disease 199–200
 Menkes disease 205–6
 multiple sclerosis (MS) 206–7
 Parkinson's disease 189–96
 polyQ disease 199–200
 prion diseases 201–3
 Wilson's disease 206
 anticholinergics 171
 anticholinesterase inhibitors 176
 antioxidants, low-molecular-weight 34
 apoptic bodies 38
 apoptic pathways 39
 apoptosis 36, 38–42, 194
 inappropriate 38
 initiation 38
 apotransferrin (APO-TF) 4
 Arabidopsis thaliana 11
 arachadonic acid metabolism 48
 Aricept 176
 aspirin 173, 176
 astroglia, glutamate uptake 145
 ataxin-1 108–9
 RNA binding site of AXH domain 109
 ataxin-2 107
 Lsm domain model 107
 ataxin-3 108
 deubiquitinating Josephin domain model 108
 ataxin-7 108
 ATP production 34–5, 89

 BACE1 knock-out mice 197
 benapryzine 171
 benzhexol 171
 benztropine 171
 blood-brain barrier 6
 bornaprine 171
 Bowman-Birk inhibitor 54, 56
 brain function, metal ions in 1–4
 BSE (bovine spongiform encephalopathy)
 122–4, 130

 CaS2+s 2–3, 134
 (CaS2+s)U4u-calmodulin 3–4
 Caenorhabditis elegans 38, 108
 caffeine in PD 69
 CAG expansions 114
 calcineurin 3
 calmodulin 3
 CaMKII 3–4
 cAMP production 47
 cannabis in MS 185
 carbonyl compounds 29
 β -carotene 34
 caspase-7 40
 caspases 40
 activation 144–5
 cell death in polyQ diseases 100–1
 cellular proteins, degradation x
 cerebellar ataxia 112

- ceruloplasmin 7–8, 150–1
 in cellular iron efflux 152
 in iron cycle 151
 structural model 151
 chemical chaperones 216
 chloroquine 177
 cholinergic release 168
 chronic wasting disease (CWD) 123
 clozaril 171
 cobalt, ion transport and storage 13
 Coenzyme A (CoA), biosynthetic pathway 157
 coffee in PD 69
 complex 1 in PD 66, 70
 copolymer-1 179
 copper
 in AD 83–8
 ion transport and storage 7–10
 trafficking in hepatocyte 9
 copper homeostasis 14–18
 PrPSCs role in 134
 copper neuromelanin 65
 copper transport proteins (CTR) 134
 CopZ 11
 CopZp 10
 COX-1/COX-2 47–8, 92–3, 147, 173
 Creb binding protein (CRP) 100
 Creutzfeldt-Jakob disease (CJD) 122–36
 Ctr1 gene 9–10
 Ctr1 protein 10
 CuS2+s 21
 Cu-Zn superoxide dismutase (SOD-1) 195, 198
 cyclin-dependent kinase 5 (cdk5) activity,
 deregulation of 92
 cyclin family members (Cdks) 36–8
 cyclooxygenases *see* COX-1/COX-2
 cytokine-mediated inflammatory processes
 in AD 92
 cytomegalovirus 184
 cytoprotection against oxidative damage
 30–5
 cytotoxins involved in Parkinsonism 73

 death-effector domains (DED) 100
 death ligand (FasL) 39
 death receptor (Fas) 39
 debilitating diseases x
 DentatoRubral and PallidoLuysian Atrophy
 (DRPLA) 179
 desferrioxamine 171
 desmethylselegiline 173
 detergent-resistant membranes (DRMs) 125
 dioxygen molecule 22
 DMT1 4, 7, 10, 12, 63

 DNA bases 29
 DNA replication 40
 donepezil 176
 dopamine 67
 aberrant oxidation 72
 agonists 170
 metabolism 168, 174
 role in Parkinson's disease 71–4
 dopamine β -hydroxylase 4
 dopamine blockers 171
 dopaminergic cell death 71
 down-regulation of pro-survival pathways 101
Drosophila melanogaster 3
 dynein 146

 EAATs 47
 Eldepryl 173
 energy-dependent process x
Enterococcus hirae 11
 E-prostanoid receptors (EP1, EP2, EP3 and
 EP4) 47
 Epstein-Barr virus 184
 ethanol in PD 70
 excitotoxicity mediated by glutamate 145
 Exelon 176
 expanded polyQ proteins, neuronal damage
 101
 expansion of non-coding trinucleotide repeats,
 diseases caused by 113
 expansion of non-coding triplets, diseases
 associated with 118–19
 expansion of unstable trinucleotide repeats 114
 experimental allergic encephalomyelitis (EAE)
 162
 experimental autoimmune encephalitis (EAE),
 animal models 206–7
 extrinsic pathway 38

 familial ALS (FALS) 138
 Familial British dementia (FBD) 88–9
 familial Creutzfeldt-Jakob disease (fCJD)
 122
 Fatal Familial Insomnia 122
 FeS2+s 23, 25, 34
 FeS3+s 21, 23
 Fenton reaction 23
 ferritin 5–7, 14, 62, 64, 158–9
 ferroportin 5
 FMRP 119
 follicular dendritic cells (FDCs) 131
 fragile X mental retardation disease, animal
 models 201
 fragile X syndrome 96, 119, 181

- frataxin 179–80
 mutations 114
 protein levels 114
 role in iron metabolism 115–18
 role in mitochondrial iron storage 118
 structure 117
 frataxin gene 115
 frataxin molecule, anionic patch 117
 free radicals 35–6
 oxygen-derived 21
 Friedreich's ataxia (FRDA) 95–6, 112–21
 animal models 200–1
 clinical spectrum 115
 diagnosis 112
 incidence 112
 molecular basis 114–18
 oxidative stress in 180
 pathophysiology 112
 prevalence 112
 therapeutic strategies 179–80
 tissue-specific pathology 115

 GAA expansion 114
 GABA 4
 galantamine 176
 genetic haemochromatosis (GH) 63
 Gerstmann-Sträussler-Scheinker syndrome 122
 glucose-6 phosphate dehydrogenase (G6PD) 33
 glutamate 44, 46
 excitotoxicity mediated by 145
 glutamate receptors 47
 glutamate transporters 47
 glutathione (GSH/GSSG) 32–3, 42, 72
 depletion of 72
 glutathione peroxidase (GPx) 32–3, 195
 glycogen synthase kinase-3 β (GSK-3 β) 179
 P-glycoprotein 63
 GSSG 42

 haem oxygenase 34
 Hallervorden-Spatz syndrome 158
 eye of the tiger 158–9
 PANK2 mutations 158
 H-chain ferritins 6
 HEAT domains 104
 HEAT repeats 103–4
 Hereditary ataxia 112
 highly active antiretroviral therapy (HAART) 164
 HIV-associated dementia (HAD) 164–5
 HLA class I and II antigens 161
 (HMG-CoA) reductase inhibitors 89
 HNE 28
 HU2uOU2u as second messenger 42

 HOIL-1 18
 holo(diferric)-transferrin molecule (HOLO-TF) 4
 homeostasis 14–18
 hormone replacement therapy 53
 human immunodeficiency virus (HIV) 125, 164
 Huntingdon's disease (HD) x
 cellular pathogenesis model 104
 frequency 102
 juvenile onset 102
 major sites of axonal loss 102
 neuropathology and motor dysfunction reversal 217
 therapeutic strategies 179
 huntingtin, model of relocation 100
 huntingtin domain structure and sequence
 comparison between species 103
 huntingtin gene 102, 104
 Huntington's disease (HD) 38, 95, 102–5, 179
 animal models 199–200
 iron accumulation in 102
 polyQ protein aggregation on 99
 relationship between CAG repeat number and age of onset 96–7
 hydrogen peroxide 32
 hydroperoxides 27
 4-hydroxy-2-alkenals 27
 8-hydroxy-2'-deoxyguanosine (8-OHdG) 29
 6-hydroxydopamine (6-OHDA) 191, 194
 hyperphosphorylated tau 178

 iatrogenic CJD (iCJD) 122
 ibuprofen 173, 176
 IGF-1 182
 indomethacin 176–7
 inflammatory pathway, molecules involved in 44–51
 inhibitor of apoptosis (IAP) 40, 42
 Interferon- β 184
 intracellular inclusion bodies 214
 intracellular protein aggregates in ALS 143–4
 intrinsic pathway 38–40
 iron
 accumulation in Huntington's disease 102
 and α -synuclein 58
 chelators 172
 dietary intake 53
 distribution in human brain 7
 homeostasis 14–18, 24
 in AD 83–8
 in Parkinson's disease 62–3
 ion transport and storage 4–7
 metabolism, frataxin role in 115–18

- iron-dependent enzymes 24
- iron-neuromelanin complex 64–5
- iron–oxygen chemistry 23
- iron regulatory protein 1 (IREG1) 5
- iron responsive elements (IREs) 7, 14, 85, 151
- iron responsive proteins (IRP-1/IRP-2) 15–16, 65, 86–7, 195
- iron transport proteins 6

- JNK/SAPK pathway 91
- JNPL3 197

- KS+s 1–2
- Kayser-Fleischer rings 9
- Kennedy's disease *see* spinobulbar muscular atrophy (SBMA)
- ketoaldehydes 27
- kinases, cyclin-dependent 36–8
- Krebs cycle 44
- Kuru 123, 130

- labile iron pool (LIP) 5
- levodopa (L-DOPA) 67, 169
- Lewy bodies ix, 54, 56–7, 63, 66
 - α -synuclein in 169
 - components of 60
- lipid peroxidation 27, 34, 91
- Lou Gehrig's disease 137

- macrophages 26
- major histocompatibility complex (MHC) 161
- malondialdehyde (MDA) 27–8
- manganese
 - in PD 66–7
 - ion transport and storage 13
- MAP kinase 36–7
- MAP kinase kinase kinase (MKKK) 36
- MAP kinase kinase (MKK) 36
- MAPK signalling 36
- matrix metalloproteinase-2 (MMP-2) 165
- melanotransferrin 66
- memory molecule 3
- Menkes disease 155–7
 - affected gene 156
 - animal models 205–6
 - ATP7a 156
 - copper link in 155–7
 - mutations 156–7
 - pathways of copper 156
 - therapeutic strategies 183
- metabotropic glutamate 171
- metal-induced oxidative stress ix
- metal ions in brain function 1–4
- metalloenzymes 4
- metalloneurochemistry 1
- metallothioneins 10
- 1-methyl-4-phenylpyridinium (MPPS+s) 191, 194
- methylmalonyl-CoA mutase 22
- Michael addition reactions 28
- microglia in ALS 147
- Mirapex 170
- mitochondria 35
- mitochondrial damage in ALS 145
- mitochondrial function in AD 89
- mitochondrial Mn superoxide dismutase (MnSOD) 71
- mitochondrial oxidative phosphorylation 70
- mitochondrion-dependent apoptosis 36
- mitogen-activated protein kinases (MAPK) 36
- mitoxantrone 184
- MnSOD knock-out mouse 195
- molybdenum ion transport and storage 13
- monoamine oxidase 173–4
- motor neurone disease 137
- motor neurons, damage pathways 146–7
- MPPS+s 191, 194
- MPTP 57, 66–7, 191, 193, 195
- multiple sclerosis (MS) 159–63
 - aetiology 184
 - animal models 206–7
 - cannabis in 185
 - cause 161
 - drug therapies 184
 - electron micrograph of myelinated nerve fibres 160
 - frequency 161
 - myelin in 161
 - pathogenic mechanisms involved 162–3
 - therapeutic strategies 184
- myelin
 - in MS 161
 - mediators 162

- NaS+s 1
- NADH CoQ reductase (complex 1) 66, 70
- NADPH 33–4
- NADPH oxidase 24
- Natalizumab 184
- nerve impulses 1

- neurodegenerative diseases ix
 and ageing 211
 hallmark of 211
 metal-associated pathology x
 neuropathological lesions 212
 objectives ix
 protein-containing deposits 30
 proteins and pathology 213
 similarities 212
see also specific diseases
- neuroferritinopathy 158–9
 T2u-weighted MRI images 159
- neurofibrillary tangles (NFTs) ix, 178, 198
- neurofibrillary tau legions 83
- neurofilament disorganization in ALS 143
- neuromelanin in PD 64
- neurotransmission mechanisms 46
- neurotrophic factors 185–6
- NF κ B 42–4, 178
- nicotine supplementation in PD 68–9
- nicotinic receptors
 in AD 177
 in PD 67
- nitrogen bases formed by reactive oxygen
 species (ROS) 29–30
- NMDA 47
- NMDA receptors 82, 176, 216
- NO synthase (NOS) reaction 25–6
- nodes of Ranvier 161
- non-coding trinucleotide repeats, diseases
 caused by expansion of 113
- non-coding triplets
 diseases associated with expansion of
 118–19
 therapeutic strategies 179–80
- non-steroidal anti-inflammatory drugs
 (NSAIDs) in AD 176–7
- NR4A2 62
- NRAMP1 12
- nuclear localization signal (NLS) 106
- nucleic acids 29
- occipital horn syndrome 183
- 6-OHDA 191, 193, 195
 hypothetical mechanism of toxicity 194
 hypothetical molecular pathways leading to
 apoptosis triggered by 194
- oligonucleotides 217
- orphenadrine 171
- oxidative damage
 cytoprotection against 30–5
 in ALS 142–3
- oxidative stress 21–52
 hypothesis 72
 in AD 89–93
 in FRDA 180
 in PD 73, 172
 reduction of 216
- oxygen-derived free radicals 21
- oxygen paradox 21
- oxygen reduction pathway 31
- P25-Cdk5 pathway 38
- Pael-R 60
- pantothenate kinase 2 (PANK2) 158
- Park 3–11, role in PD 60–2
- parkin 18, 58–9
 function of 60
 in mitochondrial function 71
 in protein degradation 59
 substrates 59
- Parkinson's disease (PD) ix, 18, 38, 53–76
 aetiology 53
 alcohol in 69
 animal models 189–96
 animal studies 53
 causes of 66
 coffee in 69
 complex 1 in 66, 70
 diet 168–9
 dopamine role in 71–4
 drug regime 168
 drug strategies 169
 early detection 168
 ethanol in 70
 genotyping 53
 idiopathic 56, 62
 incidence 53
 inherited forms 66
 intrastriatal transplants of fetal dopaminergic
 neurons 173
 iron in 63–6
 malfunctions occurring 72
 manganese in 66–7
 metal involvement 62–6
 mitochondrial dysfunction 70–1
 molecular and intracellular pathways of
 dopaminergic neurotoxins in animal models
 192
 neuromelanin in 64
 nicotinic receptors in 67
 oxidative stress in 73, 172
 Park 3–11 role in 60–2
 physical exercise 169

- Parkinson's disease (PD) (*continued*)
 protection against development 53
 proteins involved 54–62
 risk factors 53, 66–70
 side effects 171
 smoking in 67, 69
 surgical intervention 173
 synucleins in 54–5, 57–8, 66, 169, 189
 therapeutic strategies 168–74
 transgenic models 190
 treatment strategies 185
 zinc in 67
- Parlodel 170
- peripheral nervous system (PNS) 131
- Permax 170
- Peyer's patches 131
- PGEU2u 47
- phagosome 24
- Pick's disease 83
- polyglutamine 96, 214–15
- polyglutamine-protein expression inhibition 218
- polypeptide chains, possible fates of newly synthesized 215
- polyQ disease 96–7, 101, 179
 animal models 199–200
 cell death in 100–1
 proteins 105–9
- polyQ expanded proteins, neuronal damage 101
- polyQ protein aggregation
 on Huntingtin's disease 99
 structural models 97–100
- polyunsaturated fatty acids (PUFA) 27, 34
- presenilins 1 and 2 (PS1/PS2) 80, 199
- prion diseases ix, 122–36
 animal models 201–3
 animal species 122
 conformation-based inheritance 124–6
 conformation-based transmission mechanism 126–30
 copper(II)-binding site 133
 formation of aggregates 128–9
 history 123–4
 in humans 122
 mammalian 125–6
 models of PrPSCs to PrPSScs conversion 126–8
 pathways of pathogenesis 130–3
 peripheral replication 130–1
 prion-metal interactions 133–4
 protein-only hypothesis 124–6
 refolding or heterodimer model 126
 seeding or nucleation model 128
 steps in transmission 129–30
 therapeutic strategies 181
 transmigration from periphery to CNS 131–3
- prion protein
 gene 122
 plaques ix
 structure 124
- programmed cell death 38–41
- pro-survival pathways, down-regulation of 101
- prostaglandins 48
- protocycins 48
- protein aggregation 212–14
- protein carbonyl derivatives 27–9
- protein degradation mechanisms 16–17
- protein deposition diseases 50
- protein oxidation 29
- protein tyrosine phosphatase (PTP) 42
- proteolytic cleavage 214, 217
- proteolytic enzymes, targeting 217
- proteolytic processing of amyloid precursor protein (APP) 79
- protosome x
- quetiapine 171
- reactive nitrogen species (RNS) 21, 25–7, 41–4, 211
 in neurodegenerative pathologies 27
 modifications to proteins 29
 produced during inflammation 26
 second messenger 42
 targets 27–30
- reactive oxygen intermediates (ROI) 162
- reactive oxygen species (ROS) 21–5, 27–30, 41–4, 211
 base damage caused by 29
 cytotoxicity 24
 generation 57–8, 82, 216
 in neurodegenerative pathologies 27
 nitrogen bases formed by 29–30
 production 26, 89
 second messenger 42
 signalling role 44
- redox-active metals 4, 21–52
- redox potentials 23–4
- Reminyl 176
- Requip 170
- reticulocytes 17
- RING finger 18

- RING (IBR) domain 58–9
 rivastigmine 176
 RNA interference (RNAi) 217–18
- Saccharomyces cerevisiae* 9, 11
 β -secretase in AD 175
 SIAH-1/SIAH-2 60
 signalling 35–6, 41–4, 106
 Sinemet 169
 SLC11 13
 SLC30 12–13
 SLC39 11–13
 smoking in PD 67, 69
 SOD-1 *see* superoxide dismutase (SOD)
 spinobulbar muscular atrophy (SBMA) 95, 101,
 106–7, 179
 spinocerebellar ataxias 95, 106
 sporadic CJD (sCJD) 122–30
 stress-activated protein kinase pathways (SAPK)
 91
 stromal cell-derived factor-1 (SDF-1) 164
 superoxide dismutase (SOD) 4, 10, 26, 31–2, 71,
 138, 195, 198, 203–4
 and ALS 139–42
 dimers 141–2
 mutation 140, 143, 145, 147–8
 Symmetrel 171
 synaptotagmins 3
 synphilin-1, in PD 60
 synphilin-1/SIAH complex 60
 synucleins
 in modulation of dopamine release 54–5
 in neurodegenerative disease 54
 in PD 54–5, 57–8, 66, 169, 189
 synucleinopathies 54
- T helper 1/2 (Th1/Th2) cells 162
 tacrine 176
 Tasmar 170
 tau proteins 83
 Tg2576 197
 thalassaemia patients (THAL) 63
 therapeutic strategies 168–88, 215–18
 metal accumulation retardation 216
 position and prospects 215–18
see also specific diseases
 thioredoxin (Trx) system 33
 thromboxanes 48
 thymine glycol 30
 α -tocopherol 34
 transferrin polymorphism 66
 transferrin receptors (TFR) 5, 7, 14, 63
 transferrin-to cell cycle 4
 transmissible spongiform encephalopathies
 (TSEs) 122
 trehalose 216
 trinucleotide expansion diseases 95–6
 structural approach 96
 tumor necrosis factor- α (TNF- α) 162, 164
- ubiquitin 17
 ubiquitin-activating enzyme 17
 ubiquitin carboxy-terminal hydrolase-1
 (UCH-L1) 61–2, 197
 ubiquitin-conjugating enzymes 17–18
 ubiquitin-proteasome system 148
 ubiquitin-protein ligase 17
 ubiquitinated inclusions (UBIs) 144
- variant Creutzfeldt-Jakob disease (vCJD) 122,
 130–1
 distribution of PrPSScs 130
 route taken by prions through sympathetic
 nervous system 132
 vascular endothelial cell growth factor (VEGF)
 147
 VGLUTs 44
 vitamin A 34
 vitamin C 34, 177
 vitamin E 34, 177
- Wilson's disease 10, 153–5
 animal models 206
 P-type ATPase (ATP7b) 153–5
 pathways of copper 156
 structural model 154
 therapeutic strategies 183
- XIAP fragment 40
 X-ray structure 1
- yeast cells 118
- zinc
 in AD 83–8
 in PD 67
 ion transport and storage 10–13
 metabolism 13
 zinc neuromelanin 65
 ZIP family 11–12
 ZnS2+s 4, 85
 ZnT3 transporter 77
 ZnT family 12
 Zydis selegiline 173